Genmab could become a buyout target for GlaxoSmithKline, some analysts speculate, after disappointing results of their co-development drug Arzerra (ofatumumab) in a pivotal Phase III trial in refractory follicular non-Hodgkin's lymphoma (NHL).
Genmab could become a buyout target for GlaxoSmithKline, some analysts speculate, after disappointing results of their co-development drug Arzerra (ofatumumab) in a pivotal Phase III trial in refractory follicular non-Hodgkin's lymphoma (NHL).
The poor data are a setback for Genmab as refractory NHL was slated as the biggest indication for the drug...
Continued success in building biotech companies and finding big pharma buyers has convinced investors to put a record sum into Sofinnova’s latest fund.
The US FDA approved the menin inhibitor for NPM1-mutant relapsed/refractory acute myeloid leukemia.
The German company is on a roll, early data on a pair of new T cell receptors adding to its promising lead cell therapy which impressed at ESMO.
CEO Bill Anderson tells Scrip that the German group looks at potential in-licensing opportunities across every stage of the pipeline “but as you know, good value is a lot harder to come by in the late stage.”
